Paul Hopper is one of Australia’s leading entrepreneurs in biotech. He has just been involved in selling Viralytics for $500 million to Merck and Company so Alan Kohler gave him a call to find out how it all came about.
Alan Kohler is one of Australia’s most respected finance reporters. For decades readers and viewers have enjoyed his expert opinion in press, television and of course on line. His writing and interviews bring a context to the issues that matter to investors, with a personality that is often missing from other financial experts. Alan started The Constant Investor to be able to directly share his passion for discovering exciting companies.